Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
- 2020年10月04日 14:27:00
- テクノロジー
- JCN Newswire
"Highly pathogenic human coronaviruses are continuously emerging and remain a major threat to human health,"stated Daryl Thompson, Impact BioLife's Director of Scientific Initiatives and founder of advanced research company GRDG Sciences, LLC ("GRDG"). Impact BioLife is a wholly owned subsidiary of Impact BioMedical. "Our pan-coronavirus vaccine is designed to allow us to not only protect against COVID-19, which is likely here to stay, but also allow for us to quickly respond to any outbreaks of a virus of this type in the future."
Coronaviruses are a large family of viruses and are common throughout the world. There are currently seven known human coronaviruses that can make people sick. Common human coronaviruses, including types 229E, NL63, OC43, and HKU1, usually cause mild to moderate upper-respiratory tract illnesses, while MERS-CoV, SARS-CoV, and now SARS-CoV2 can cause more severe pulmonary diseases.
"COVID-19 has already cost more than one million lives and continues to disrupt the $133 trillion global economy,"commented Jason Grady, COO of DSS. "A successful pan-coronavirus vaccine could save countless lives while lessening or even preventing the types of disruptions we have seen this year that have impacted nearly everyone on the planet."
Innate Immune's orally delivered pan-coronavirus vaccine has a well demonstrated safety profile and is designed to quickly be scaled for global distribution, ease of manufacturing, and high degree of stability. Innate Immune has gathered a globally recognized team of virologists to complete the research necessary to bring this vaccine to market.
"The need for a solution to COVID-19 and potential future human coronaviruses is clear. We believe this vaccine can provide that solution while remaining economically affordable, ensuring availability across the globe"stated Chan Heng Fai, Chairman of DSS.
GRDG's Chief Scientific Advisor Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC commented, "This pan-coronavirus vaccine is designed to boost a human's innate ability to fight viruses such as SARS-CoV2 by activating all phases of the human immune system. If successful, it could allow us to prevent further deaths and global economic disruptions from coronaviruses."
GRDG is a specialized research team that focuses on developing solutions for biodefense under the guidelines of the Project BioShield Act, Event 201, and Potomac Institute for Policy Studies.
GRDG performs rapid analysis and research by using advanced algorithms and the most complete databases in the world. The team operates in a lean and efficient manner and when necessary utilizes the top contract research organizations to deliver solid results that are robust and accurate.
About Impact BioMedical, Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases. For more information on Impact BioMedical visit http://impbio.com/.
About Document Security Systems, Inc.
DSS is a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman and largest shareholder, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of $25 billion. For more information on DSS visit http://www.dsssecure.com.
Investor Contact:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
神田正輝「旅サラダ」”年齢いじり”に63歳浅野ゆう子「もう、どういうこと?」
大谷翔平選手の元同僚が違法賭博か 水原被告と同じ胴元通じ 米報道
ドジャース連敗ストップで今季30勝目、大谷翔平13号ソロも追いつかれ終盤勝ち越し
橋下徹氏、水原一平被告乗車のナンバー「777」に「もうちょっと配慮してあげないと…」
【阪神】佐藤輝明、2軍降格後7打席目で初安打 2戦連続の「4番三塁」出場でマルチ安打記録
「和尚」千原せいじテレビ出演 なぜ? これからどうする?
成田悠輔氏、東大学園祭自身講演会への「反対運動」に”衝撃挑発”ネット騒然
神田正輝「旅サラダ」13回出演”63歳大女優”を絶賛
63歳浅野ゆう子「旅サラダ」神田正輝からの“シビアな一言”に「なんでそんなことを…」
【カルディおすすめ】濃厚な甘さがやみつきになる桃商品3選♪
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
大谷翔平が不運な判定で2度見逃し三振 「えん罪退場」で話題の球審は引き揚げる大谷にブチギレ
ヒカル、浮気相手とのLINE流出にドン引きの声「キモすぎる」「吐きそう」
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
吉野家が「マスク外し強要疑惑」でプチ炎上、店員さんに聞いてみると……
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
時代劇の常識を覆す!仇討ち・無礼討ちの厳格なルール
元めちゃイケメンバーの三中元克(32)現在は何をしているのか調べてみた!
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
藤田ニコル「脱ぐ予定なかったのですが気づいたらノリノリで…」ヒョウ柄水着姿に大反響
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
ヒカル、浮気相手とのLINE流出にドン引きの声「キモすぎる」「吐きそう」
ガーシー、またも綾野剛の暴露写真でネット歓喜「この写真見て笑っちゃう」
大谷翔平が不運な判定で2度見逃し三振 「えん罪退場」で話題の球審は引き揚げる大谷にブチギレ
元めちゃイケメンバーの三中元克(32)現在は何をしているのか調べてみた!
完全にダマされた! 『ラヴィット!』あのちゃん“事故レベル”大暴走は『水ダウ』遠隔操作のしわざだった ネットも納得
73歳神田正輝「旅サラダ」生放送で“12歳下俳優”から呼び捨てされ激論
ドジャース連敗ストップで今季30勝目、大谷翔平13号ソロも追いつかれ終盤勝ち越し
神田正輝「旅サラダ」”年齢いじり”に63歳浅野ゆう子「もう、どういうこと?」
成田悠輔氏、東大学園祭自身講演会への「反対運動」に”衝撃挑発”ネット騒然
ドジャース戦の球審は33歳!「相当優秀」解説者もびっくり 超異例30歳でMLB審判員に昇格
大谷翔平選手の元同僚が違法賭博か 水原被告と同じ胴元通じ 米報道
63歳浅野ゆう子「旅サラダ」神田正輝からの“シビアな一言”に「なんでそんなことを…」
【鹿島】10年間ホームで勝てていない首位神戸戦にポポビッチ監督「昨年の敗戦は関係ない」
【巨人】新外国人ヘルナンデスが来日初実戦 3軍戦「4番指名打者」で1四球1打点
【阪神】佐藤輝明、2軍降格後7打席目で初安打 2戦連続の「4番三塁」出場でマルチ安打記録
「速すぎて捕れない」昨夜4盗塁のデラクルス、出塁なしも剛速球でポテンシャルの高さを発揮